Company Info

Allergan, plc

Drug Discovery & Development

Overview

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Contributions

Contributors

Contributions

15 Contributions1 / 1

FDA Approval

Allergan Receives FDA Approval for Migraine Treatment

Allergan, plc

PR-M01-20-NI-001Jan 2, 2020

Collaboration

Exicure and Allergan Enter Into Collaboration, Option and License Agreement to Discover and Develop SNA-based Treatments for Hair Loss Disorders

Allergan, plc

PR-M11-19-NI-013-1960Nov 14, 2019

FDA Approval

Allergan Announces FDA Approval of AVYCAZ® (ceftazidime and avibactam) for Pediatric Patients

Allergan, plc

PR-M03-19-NI-054Mar 20, 2019

Data

Allergan Presents Data From Seven Abstracts At The 2019 American Academy of Dermatology (AAD) in Washington D.C.

Allergan, plc

PR-M03-19-NI-004Mar 1, 2019

Response

Allergan Responds to Public Shareholder Letter

Allergan, plc

PR-M02-19-NI-047Feb 21, 2019

Clinical Study

Allergan Launches Personalized Study Approach for Clinical Research Programs in Inflammatory Bowel Disease

Allergan, plc

PR-M10-18-NI-024Oct 8, 2018

Appointment

Allergan Appoints Neurobiology Expert Michael E. Greenberg, PhD to its Board of Directors as Part of Active Board Refreshment Process

Allergan, plc

PR-M08-18-NI-096Aug 22, 2018

Collaboration

Allergan and Editas Medicine Announce Exercise of Options to Jointly Develop CRISPR Genome Editing Experimental Medicine EDIT-101

Allergan, plc

PR-M08-18-NI-062Aug 17, 2018

Fast Track

Allergan Receives FDA Fast Track Designation for AGN-241751 for the Treatment of Major Depressive Disorder (MDD)

Allergan, plc

PR-M07-18-NI-080Jul 24, 2018

Clinical Data

Allergan Announces Positive Topline Phase 3 Clinical Data for Bimatoprost SR (Sustained-Release) Implant

Allergan, plc

PR-M06-18-NI-051Jun 14, 2018

Drug Delivery

Allergan Announces Launch of the TrueTear® Intranasal Neurostimulation Device During 2018 ASCRS-ASOA Annual Meeting

Allergan, plc

PR-M04-18-NI-55Apr 17, 2018

Results

Allergan and Richter Announce Positive Topline Results from Third of Three Pivotal Trials of Cariprazine in Bipolar I Depression

Allergan, plc

PR-M04-18-NI-018Apr 5, 2018

Earnings

Allergan to Report First Quarter 2018 Earnings and Host Conference Call and Webcast

Allergan, plc

PR-M04-18-NI-012Apr 4, 2018

NDA

FDA Acceptance of Medicines360's Filing for supplemental New Drug Application for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg

Allergan, plc

PR-M02-18-NI-108Feb 28, 2018

FDA Approval

FDA Approves AVYCAZ® (ceftazidime and avibactam) for the Treatment of Patients with Hospital-Acquired Bacterial Pneumonia

Allergan, plc

PR-M02-18-NI-029Feb 8, 2018

1 / 1

0 Contributors1 / 0

No authors found

1 / 0

Nice Insight is the market research division of That's Nice LLC, the leading marketing agency serving life sciences.

Explore

About Us Nice Insight That's Nice

Reach Our Team

My Account

Subscribe for the newsletter

Subscribe for the Newsletter

Mobile Navigation

Company Info

Allergan, plc

Drug Discovery & Development

Overview

FDA Approval

Allergan Receives FDA Approval for Migraine Treatment

Allergan, plc

Collaboration

Exicure and Allergan Enter Into Collaboration, Option and License Agreement to Discover and Develop SNA-based Treatments for Hair Loss Disorders

Allergan, plc

FDA Approval

Allergan Announces FDA Approval of AVYCAZ® (ceftazidime and avibactam) for Pediatric Patients

Allergan, plc

Data

Allergan Presents Data From Seven Abstracts At The 2019 American Academy of Dermatology (AAD) in Washington D.C.

Allergan, plc

Response

Allergan Responds to Public Shareholder Letter

Allergan, plc

Clinical Study

Allergan Launches Personalized Study Approach for Clinical Research Programs in Inflammatory Bowel Disease

Allergan, plc

Appointment

Allergan Appoints Neurobiology Expert Michael E. Greenberg, PhD to its Board of Directors as Part of Active Board Refreshment Process

Allergan, plc

Collaboration

Allergan and Editas Medicine Announce Exercise of Options to Jointly Develop CRISPR Genome Editing Experimental Medicine EDIT-101

Allergan, plc

Fast Track

Allergan Receives FDA Fast Track Designation for AGN-241751 for the Treatment of Major Depressive Disorder (MDD)

Allergan, plc

Clinical Data

Allergan Announces Positive Topline Phase 3 Clinical Data for Bimatoprost SR (Sustained-Release) Implant

Allergan, plc

Drug Delivery

Allergan Announces Launch of the TrueTear® Intranasal Neurostimulation Device During 2018 ASCRS-ASOA Annual Meeting

Allergan, plc

Results

Allergan and Richter Announce Positive Topline Results from Third of Three Pivotal Trials of Cariprazine in Bipolar I Depression

Allergan, plc

Earnings

Allergan to Report First Quarter 2018 Earnings and Host Conference Call and Webcast

Allergan, plc

NDA

FDA Acceptance of Medicines360's Filing for supplemental New Drug Application for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg

Allergan, plc

FDA Approval

FDA Approves AVYCAZ® (ceftazidime and avibactam) for the Treatment of Patients with Hospital-Acquired Bacterial Pneumonia

Allergan, plc

No authors found

No authors found

FDA Approval

Allergan Receives FDA Approval for Migraine Treatment

Allergan, plc

Collaboration

Exicure and Allergan Enter Into Collaboration, Option and License Agreement to Discover and Develop SNA-based Treatments for Hair Loss Disorders

Allergan, plc

FDA Approval

Allergan Announces FDA Approval of AVYCAZ® (ceftazidime and avibactam) for Pediatric Patients

Allergan, plc

Data

Allergan Presents Data From Seven Abstracts At The 2019 American Academy of Dermatology (AAD) in Washington D.C.

Allergan, plc

Response

Allergan Responds to Public Shareholder Letter

Allergan, plc

Clinical Study

Allergan Launches Personalized Study Approach for Clinical Research Programs in Inflammatory Bowel Disease

Allergan, plc

Appointment

Allergan Appoints Neurobiology Expert Michael E. Greenberg, PhD to its Board of Directors as Part of Active Board Refreshment Process

Allergan, plc

Collaboration

Allergan and Editas Medicine Announce Exercise of Options to Jointly Develop CRISPR Genome Editing Experimental Medicine EDIT-101

Allergan, plc

Fast Track

Allergan Receives FDA Fast Track Designation for AGN-241751 for the Treatment of Major Depressive Disorder (MDD)

Allergan, plc